Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Other Accumulated Expenses of $3.3 million for Q1 2026, up 400.92% year-over-year from $651000.0 in Q1 2025, and down 58.5% quarter-over-quarter from $7.9 million in Q4 2025.
Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Revolution Medicines' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 400.92% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 400.92% YoY), while the FY2025 annual figure was $7.9 million, up 1247.86% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $3.3 million, down from $7.9 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $8.2 million in Q3 2025, with the low at $280000.0 in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $647000.0 (2022), against an average of $1.8 million.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 85.04% in 2024, then jumped 1247.86% in 2025.
- Revolution Medicines' Other Accumulated Expenses stood at $505000.0 in 2022, then jumped by 671.49% to $3.9 million in 2023, then tumbled by 85.04% to $583000.0 in 2024, then surged by 1247.86% to $7.9 million in 2025, then sank by 58.5% to $3.3 million in 2026.
- Business Quant data shows RVMD's Other Accumulated Expenses at $3.3 million in Q1 2026, $7.9 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.15 Mn |
| Mar 31, 2026 | 3.26 Mn |
| Dec 31, 2025 | 7.86 Mn |
| Sep 30, 2025 | 8.24 Mn |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 651,000.00 |
| Dec 31, 2024 | 583,000.00 |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 657,000.00 |
| Mar 31, 2024 | 744,000.00 |
| Dec 31, 2023 | 3.90 Mn |
| Sep 30, 2023 | 480,000.00 |
| Jun 30, 2023 | 350,000.00 |
| Mar 31, 2023 | 397,000.00 |
| Dec 31, 2022 | 505,000.00 |
| Sep 30, 2022 | 488,000.00 |
| Jun 30, 2022 | 647,000.00 |
| Mar 31, 2022 | 280,000.00 |
| Dec 31, 2021 | 311,000.00 |
| Sep 30, 2021 | 125,000.00 |